<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051426</url>
  </required_header>
  <id_info>
    <org_study_id>112-06</org_study_id>
    <nct_id>NCT02051426</nct_id>
  </id_info>
  <brief_title>Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans</brief_title>
  <acronym>NMDAR</acronym>
  <official_title>Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of compounds having agonistic activity at the glycine site associated with the
      N-methyl-D-aspartate receptor (NMDAR) is presently assessed in psychiatric disorders. In
      contrast to NMDAR antagonists, the neuropsychiatric effects of NMDAR agonists in the healthy
      human organism are not known. The investigators studied neuropsychiatric and neurochemical
      effects of the NMDAR-glycine site obligatory co-agonist D-serine (DSR) in healthy subjects
      using a randomized, controlled crossover challenge design including a baseline assessment day
      and two treatment administration days (DSR and placebo in randomized order). Thirty-five
      subjects aged 23-29 years participated in the study and received a 2.1g orally administered
      DSR dose. The main outcome measures were the changes in scores of mood-related Visual
      Analogue Scale (VAS), Continuous Performance Test - Identical Pairs (CPT-IP), and Rey
      Auditory Verbal Learning Test (RAVLT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study employed a randomized, double-blind, placebo controlled crossover design according
      to which, following a baseline assessment session, subjects were tested under two acute
      treatment conditions on two separate days. Following the baseline assessment day, 16 subjects
      were randomized, using a computer-generated random number sequence, to receive during test
      day 1 DSR and 19 to receive placebo. During test day 2, these two groups of subjects were
      crossed over to receive the alternative experimental treatment. The time intervals between
      the baseline assessment day, test day 1 and test day 2 were two to three weeks and 1 month
      respectively, in order to avoid the possibility of any carry-over effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours</measure>
    <time_frame>Baseline, 2 hours post intervention</time_frame>
    <description>The subject was asked to point on the VAS scale according to his anxiety level. VAS anxiety scale 0 to 10 ( 0 [no anxiety] to 10 [maximum anxiety] ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cognitive Function- CPT-IP D-prime Score - From Baseline to 2 Hours</measure>
    <time_frame>Baseline, 2 hours post intervention</time_frame>
    <description>The &quot;d-prime score&quot; is a score given to each participant on a scale of 0.0 - 1.0 in which discrimination sensitivity is measured. A score of 0 equates to no sensitivity whereas a score of 1.0 equates to perfect sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7) - From Baseline to 2 Hours</measure>
    <time_frame>Baseline, 2 hours post intervention</time_frame>
    <description>RAVLT measures short term verbal memory, verbal learning, susceptibility to (proactive and retroactive) interference, retention of information after a certain period of time during which other activities are performed and recognition memory. The test consists of a list of 15 common nouns, which are read to the subject in five consecutive trials (trials 1 through 5); each reading is followed by a free-recall task. In trial 6, an interface list of 15 new common nouns is presented, followed by free recall of these new nouns. In trial 7, without additional reading, subjects are again asked to recall the first list. Twenty minutes later, without an additional reading, subjects are asked to recall once more the first list (trial 8). The RAVLT score range from 0-90 correctly recalled words. For trial 7 the score ranges from 0 to 15 correctly recalled words.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>D-serine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single P.O. administration of D-serine (2.1g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single P.O. administration of corn starch</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>single P.O. administration of D-serine (2.1g)</description>
    <arm_group_label>D-serine</arm_group_label>
    <other_name>DSR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single P.O. administration of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>corn starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:

          -  history of psychiatric, medical, neurological illness or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uriel Heresco-Levy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzog Hospital</affiliation>
  </overall_official>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <results_first_submitted>February 26, 2014</results_first_submitted>
  <results_first_submitted_qc>November 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2014</results_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropsychiatric effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D-serine First, Then Placebo</title>
          <description>D-serine (2.1g), then Placebo (corn starch)</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then D-serine</title>
          <description>corn starch, then D-serine (2.1g)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 1 Month</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>16 participants received DSR then 1month later received placebo; whereas19 participants received placebo then 1 month later received DSR. The assessments were performed at baseline assessment day and 2 hours after the experimental treatment administration (test day1&amp;2). Outcome analysis was D-serine versus Placebo effects for total 35 participants.</population>
      <group_list>
        <group group_id="B1">
          <title>D-serine First, Then Placebo</title>
          <description>D-serine (2.1g), then placebo (corn starch)</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then D-serine</title>
          <description>corn starch, then D-serine (2.1g)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.58" spread="3.0"/>
                    <measurement group_id="B2" value="26.58" spread="3.0"/>
                    <measurement group_id="B3" value="26.58" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours</title>
        <description>The subject was asked to point on the VAS scale according to his anxiety level. VAS anxiety scale 0 to 10 ( 0 [no anxiety] to 10 [maximum anxiety] ).</description>
        <time_frame>Baseline, 2 hours post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>D-serine (2.1g)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>corn starch</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours</title>
          <description>The subject was asked to point on the VAS scale according to his anxiety level. VAS anxiety scale 0 to 10 ( 0 [no anxiety] to 10 [maximum anxiety] ).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cognitive Function- CPT-IP D-prime Score - From Baseline to 2 Hours</title>
        <description>The &quot;d-prime score&quot; is a score given to each participant on a scale of 0.0 - 1.0 in which discrimination sensitivity is measured. A score of 0 equates to no sensitivity whereas a score of 1.0 equates to perfect sensitivity.</description>
        <time_frame>Baseline, 2 hours post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>D-serine (2.1g)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>corn starch</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Function- CPT-IP D-prime Score - From Baseline to 2 Hours</title>
          <description>The &quot;d-prime score&quot; is a score given to each participant on a scale of 0.0 - 1.0 in which discrimination sensitivity is measured. A score of 0 equates to no sensitivity whereas a score of 1.0 equates to perfect sensitivity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5" spread=".2"/>
                    <measurement group_id="O2" value="0" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7) - From Baseline to 2 Hours</title>
        <description>RAVLT measures short term verbal memory, verbal learning, susceptibility to (proactive and retroactive) interference, retention of information after a certain period of time during which other activities are performed and recognition memory. The test consists of a list of 15 common nouns, which are read to the subject in five consecutive trials (trials 1 through 5); each reading is followed by a free-recall task. In trial 6, an interface list of 15 new common nouns is presented, followed by free recall of these new nouns. In trial 7, without additional reading, subjects are again asked to recall the first list. Twenty minutes later, without an additional reading, subjects are asked to recall once more the first list (trial 8). The RAVLT score range from 0-90 correctly recalled words. For trial 7 the score ranges from 0 to 15 correctly recalled words.</description>
        <time_frame>Baseline, 2 hours post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>D-serine (2.1g)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>corn starch</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7) - From Baseline to 2 Hours</title>
          <description>RAVLT measures short term verbal memory, verbal learning, susceptibility to (proactive and retroactive) interference, retention of information after a certain period of time during which other activities are performed and recognition memory. The test consists of a list of 15 common nouns, which are read to the subject in five consecutive trials (trials 1 through 5); each reading is followed by a free-recall task. In trial 6, an interface list of 15 new common nouns is presented, followed by free recall of these new nouns. In trial 7, without additional reading, subjects are again asked to recall the first list. Twenty minutes later, without an additional reading, subjects are asked to recall once more the first list (trial 8). The RAVLT score range from 0-90 correctly recalled words. For trial 7 the score ranges from 0 to 15 correctly recalled words.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread=".3"/>
                    <measurement group_id="O2" value=".3" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>at the end of test days 1 and 2</time_frame>
      <desc>Udvalg for Kliniske Undersogelser (UKU) Side Effects Rating Scale</desc>
      <group_list>
        <group group_id="E1">
          <title>D-serine</title>
          <description>D-serine (2.1g)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>corn starch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Uriel Heresco-Levy, M.D.</name_or_title>
      <organization>Herzog Hospital</organization>
      <phone>+972-2-5316906</phone>
      <email>urielh@ekmd.huji.ac.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

